CA2468907A1 - Effecteurs d'immunite innee - Google Patents

Effecteurs d'immunite innee Download PDF

Info

Publication number
CA2468907A1
CA2468907A1 CA002468907A CA2468907A CA2468907A1 CA 2468907 A1 CA2468907 A1 CA 2468907A1 CA 002468907 A CA002468907 A CA 002468907A CA 2468907 A CA2468907 A CA 2468907A CA 2468907 A1 CA2468907 A1 CA 2468907A1
Authority
CA
Canada
Prior art keywords
peptide
seq
expression
protein
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468907A
Other languages
English (en)
Inventor
Dawn Bowdish
B. Brett Finlay
Robert E. W. Hancock
Jon-Paul Steven Powers
Carrie Melissa Rosenberger
Monisha Gough Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468907A1 publication Critical patent/CA2468907A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

L'invention se rapporte à un procédé d'identification d'un polynucléotide ou d'un schéma de polynucléotides régulé par au moins un agent inducteur de sepsie ou d'inflammation et inhibé par un peptide. L'invention concerne un procédé d'identification d'un schéma d'expression de polynucléotide pour l'inhibition d'une réponse inflammatoire ou septique. Ce procédé consiste à mettre en contact des cellules avec LPS, LTA, CpG ADN et/ou des microbes intacts ou des composants microbiens en présence ou en l'absence d'un peptide ; à détecter un schéma d'expression de polynucléotide pour les cellules en la présence ou en l'absence du peptide, le schéma en la présence du peptide représentant l'inhibition d'une réponse inflammatoire ou septique. L'invention porte aussi sur des composés et des agents identifiés par les procédés de l'invention. Dans un autre aspect, l'invention concerne également des procédés et des composés permettant d'améliorer l'immunité innée d'un sujet.
CA002468907A 2001-12-03 2002-12-02 Effecteurs d'immunite innee Abandoned CA2468907A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
US60/336,632 2001-12-03
PCT/CA2002/001830 WO2003048383A2 (fr) 2001-12-03 2002-12-02 Effecteurs d'immunite innee

Publications (1)

Publication Number Publication Date
CA2468907A1 true CA2468907A1 (fr) 2003-06-12

Family

ID=23316965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468907A Abandoned CA2468907A1 (fr) 2001-12-03 2002-12-02 Effecteurs d'immunite innee

Country Status (12)

Country Link
EP (1) EP1470249A2 (fr)
JP (1) JP2005536985A (fr)
KR (1) KR20040077669A (fr)
CN (2) CN101215601A (fr)
AU (1) AU2002365675B2 (fr)
CA (1) CA2468907A1 (fr)
HK (1) HK1075677A1 (fr)
IL (1) IL162300A0 (fr)
NZ (2) NZ533721A (fr)
SG (1) SG159382A1 (fr)
WO (1) WO2003048383A2 (fr)
ZA (1) ZA200404919B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025607A1 (fr) * 2002-12-02 2005-03-24 The University Of British Columbia Methodes permettant de stimuler l'immunite innee a l'aide de peptides cationiques
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901933A (zh) * 2003-09-12 2007-01-24 英属哥伦比亚大学 用阳离子肽刺激先天免疫的方法
WO2006005190A1 (fr) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Procede de criblage destine a la protection contre l'infection microbienne
WO2006137444A1 (fr) * 2005-06-22 2006-12-28 Seikagaku Corporation Procédé d’élimination de la radioactivité du lipoarabinomannane et application de ce procédé
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
US8124721B2 (en) 2005-10-04 2012-02-28 Inimex Pharmaceuticals Inc. Peptides for modulating innate immunity
NZ574758A (en) 2006-08-21 2012-03-30 Univ British Columbia Small cationic antimicrobial peptides
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2009057695A1 (fr) * 2007-10-30 2009-05-07 Olympus Corporation Procédé de détection d'un adénome ou d'un cancer par analyse génétique
WO2010026489A1 (fr) * 2008-09-05 2010-03-11 The University Of British Columbia Modulateurs d'immunité innée
WO2010042534A1 (fr) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides et procédés d'utilisation
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
WO2023063994A1 (fr) * 2021-10-13 2023-04-20 Phenomune, LLC Méthodes de test pour la détermination du phénotype t2r et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
WO2005025607A1 (fr) * 2002-12-02 2005-03-24 The University Of British Columbia Methodes permettant de stimuler l'immunite innee a l'aide de peptides cationiques

Also Published As

Publication number Publication date
AU2002365675A1 (en) 2003-06-17
ZA200404919B (en) 2006-05-31
EP1470249A2 (fr) 2004-10-27
WO2003048383A3 (fr) 2004-08-05
SG159382A1 (en) 2010-03-30
CN101215601A (zh) 2008-07-09
AU2002365675B2 (en) 2007-04-05
NZ563261A (en) 2008-08-29
WO2003048383A2 (fr) 2003-06-12
IL162300A0 (en) 2005-11-20
CN100357324C (zh) 2007-12-26
NZ533721A (en) 2007-12-21
HK1075677A1 (en) 2005-12-23
CN1615368A (zh) 2005-05-11
KR20040077669A (ko) 2004-09-06
JP2005536985A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
US20070134261A1 (en) Effectors of innate immunity
CA2468907A1 (fr) Effecteurs d'immunite innee
TWI665304B (zh) 抗發炎胜肽及包含其之成分（二）
US6187557B1 (en) c-IAP1 and c-IAP2: inhibitors of apoptosis
US20050201975A1 (en) Medical treatment
VanCompernolle et al. Inhibition of HIV infection by caerin 1 antimicrobial peptides
US6821736B1 (en) Inhibitors of apoptosis
US7687454B2 (en) Effectors of innate immunity determination
US20070190533A1 (en) Effectors of innate immunity
ZA200602754B (en) Effectors of innate immunity determination
AU2007201885A1 (en) Effectors of innate immunity
Marquardt Hypervirulent Clostridioides difficile induces a multifaceted response in human mucosal-associated invariant T cells
WO2020032894A1 (fr) Peptide immunomodulateur dérivé d'une séquence précurseur de terminal amino cxcl8
AU2004245959A1 (en) Methods for screening inhibitors of apoptosis
WO2020032895A2 (fr) Peptide immunomodulateur dérivé d'une séquence précurseur d'extrémité n-terminale de cxcl14
WO2020032897A1 (fr) Peptide immunomodulateur dérivé d'une séquence précurseur amino-terminale de cxcl17
AMBACH et al. O. 1 The serine phosphatases PPl and PP2A associate with and activate the actin-binding protein cofilin in human T lymphocytes
JPWO2003070947A1 (ja) Ｃｇｉ−９４と相互作用するアポトーシス促進物質および抑制物質ならびにそれらのスクリーニング法
Polley Allergen Proteinases and Allergic Airway Inflammation: Signaling via Proteinase-Activated Receptors
Conti CLR16. 2: The identification, characterization, and functional analysis of a novel regualtor of T cell activation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued